Gilead and Merck’s Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials
Event summary
- Gilead and Merck’s once-weekly oral HIV treatment regimen of islatravir/lenacapavir (ISL/LEN) maintained virological suppression in adults with HIV who switched from standard antiretroviral therapy, according to Phase 3 ISLEND-1 and ISLEND-2 trial results.
- The trials showed that ISL/LEN was non-inferior to BIKTARVY® (bictegravir/emtricitabine/tenofovir alafenamide) in maintaining virologic suppression at Week 48.
- ISL/LEN demonstrated a similar safety profile to comparator regimens, with no new safety concerns identified.
- The data will form the basis of regulatory submissions for the investigational combination therapy.
The big picture
The successful Phase 3 trial results for ISL/LEN represent a significant advancement in HIV treatment options, potentially offering the first once-weekly oral single-tablet regimen. This innovation aligns with broader industry trends toward long-acting therapies and patient-centric treatment regimens. The strategic partnership between Gilead and Merck leverages their respective strengths in antiretroviral research to address evolving needs in HIV management.
What we're watching
- Regulatory Approval
- The pace at which regulatory authorities review and approve the once-weekly oral HIV treatment regimen of islatravir/lenacapavir will determine its market entry timeline.
- Market Adoption
- Whether ISL/LEN can gain significant market share against existing daily oral antiretroviral regimens, given its once-weekly dosing advantage and patient-reported treatment satisfaction.
- Competitive Dynamics
- How Gilead and Merck’s partnership will influence the competitive landscape in HIV treatment, particularly against established therapies like BIKTARVY®.